AbbVie (ABBV) Tax Provisions (2012 - 2026)
AbbVie (ABBV) posted quarterly Tax Provisions of $342.0 million for Q1 2026, down 8.06% year-over-year from $372.0 million in Q1 2025, and down 59.91% quarter-over-quarter from $853.0 million in Q4 2025.
AbbVie (ABBV) Tax Provisions (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Tax Provisions for 15 consecutive years, with $342.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions fell 8.06% year-over-year to $342.0 million; the TTM figure through Mar 2026 stood at $2.3 billion (up 501.72% YoY), while the FY2025 annual figure was $2.4 billion, up 514.74% from the prior year.
- Tax Provisions fell to $342.0 million in Q1 2026 per ABBV's latest filing, from $853.0 million in the prior quarter.
- Across five years, Tax Provisions topped out at $853.0 million in Q4 2025 and bottomed at -$2.2 billion in Q4 2024.
- Historically, Tax Provisions has averaged $322.5 million across 5 years, with a median of $448.0 million in 2022.
- On a YoY basis, Tax Provisions climbed as much as 202.33% in 2024 and fell as far as 678.87% in 2024.
- AbbVie's Tax Provisions stood at $493.0 million in 2022, then decreased by 21.3% to $388.0 million in 2023, then sank by 678.87% to -$2.2 billion in 2024, then surged by 137.98% to $853.0 million in 2025, then tumbled by 59.91% to $342.0 million in 2026.
- Business Quant data shows ABBV's Tax Provisions at $342.0 million in Q1 2026, $853.0 million in Q4 2025, and $526.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.81 Bn | 632.06 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 470.36 Bn | 463.79 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 375.71 Bn | 368.57 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 303.50 Bn | 295.81 Bn | 11.24 Bn | 1.01 Bn |
| 5 | Astrazeneca | 257.38 Bn | 252.48 Bn | 12.86 Bn | 291.00 Mn |
| 6 | Amgen | 236.44 Bn | 222.45 Bn | 7.24 Bn | 393.00 Mn |
| 7 | Gilead Sciences | 181.93 Bn | 178.75 Bn | 6.22 Bn | 242.00 Mn |
| 8 | Pfizer | 159.38 Bn | 147.68 Bn | 10.94 Bn | -407.00 Mn |
| 9 | Gsk | 106.17 Bn | 102.00 Bn | 8.24 Bn | 266.99 Mn |
| 10 | Sanofi | 55.13 Bn | 47.75 Bn | 10.79 Bn | -524.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 662.00 Mn |
| Mar 31, 2026 | 342.00 Mn |
| Dec 31, 2025 | 853.00 Mn |
| Sep 30, 2025 | 526.00 Mn |
| Jun 30, 2025 | 613.00 Mn |
| Mar 31, 2025 | 372.00 Mn |
| Dec 31, 2024 | -2.25 Bn |
| Sep 30, 2024 | 520.00 Mn |
| Jun 30, 2024 | 773.00 Mn |
| Mar 31, 2024 | 383.00 Mn |
| Dec 31, 2023 | 388.00 Mn |
| Sep 30, 2023 | 172.00 Mn |
| Jun 30, 2023 | 583.00 Mn |
| Mar 31, 2023 | 572.00 Mn |
| Dec 31, 2022 | 493.00 Mn |
| Sep 30, 2022 | 448.00 Mn |
| Jun 30, 2022 | 255.00 Mn |
| Mar 31, 2022 | 436.00 Mn |
| Dec 31, 2021 | 226.00 Mn |
| Sep 30, 2021 | 508.00 Mn |